Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
City of Hope Medical Center
Baylor Research Institute
Hoosier Cancer Research Network
University of Kansas Medical Center
Eli Lilly and Company
Beth Israel Deaconess Medical Center
Sun Yat-sen University
UNICANCER
Eli Lilly and Company
Hoosier Cancer Research Network
The National Center of Oncology, Azerbaijan
RenJi Hospital
Fudan University
RenJi Hospital
Fudan University
Assiut University
Fudan University
Emory University
National Cancer Institute, Slovakia
Incyte Corporation
Fudan University
Fudan University
Eli Lilly and Company
The Netherlands Cancer Institute
The Netherlands Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ottawa Hospital Research Institute
Dana-Farber Cancer Institute
Hebei Medical University Fourth Hospital
Massachusetts General Hospital
National Taiwan University Hospital
Fudan University
Louisiana State University Health Sciences Center Shreveport
Canadian Cancer Trials Group
Eli Lilly and Company
Eli Lilly and Company
University of Washington
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Centre Jean Perrin
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Shandong Cancer Hospital and Institute
Ohio State University Comprehensive Cancer Center
Columbia University
Masonic Cancer Center, University of Minnesota
National Cancer Center, Korea
Massachusetts General Hospital